Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Assembling New Commercial Team For Move Into Dermatology

Executive Summary

The big pharma is moving into a new therapy area – dermatology – as part of a three-pronged strategy in Inflammation & Immunology that also includes rheumatology and gastroenterology. Pfizer’s first product for dermatology, crisaborole for atopic dermatitis, could launch next year.

Advertisement

Related Content

Pfizer's Xeljanz: The Slow Road To Blockbuster Status
Pfizer’s Eucrisa Approval By FDA Adds New Dermatology Anchor
Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Atopic Dermatitis Market Snapshot: The Next Multi-Billion Dollar Opportunity
GSK's Immunology Strategy Edges Closer To Delivering
Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
Xeljanz Development Plans Scaled Back By Pfizer

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel